EMOA : 161128-emotra-pm-horizon-2020-application-rejected-en

Press release from Emotra AB (publ) Göteborg, November 28, 2016

European Commission Horizon 2020 - application rejected

As previously notified, Emotra AB was granted 50 kEUR to carry out a feasibility study to investigate the possibility of widening the indication spectrum for EDOR® to also encompass children and young people up to 20 years of age. A clinical multi-centre study, EUDOR-Y, exclusively for children and young people from 12 to 20 years of age has now been planned. Broadening the indication range for EDOR® to encompass younger people has long-term strategic importance for Emotra. This would lead to an increase in EDOR®'s future market, but most importantly it would mean finding a tool with which to identify depressed European youths who are at risk of committing suicide. More and more young Europeans are committing suicide, with catastrophic consequences for their families and loved ones.

The feasibility study also included a review of the conditions to further develop the hardware and software, and to develop "EDOR® Interconnect", a global communication platform that will facilitate Emotra's communication with clinical departments and serve them in different parts of the world.

After completing our feasibility study, the Company submitted its application on October 7, 2016 for appr. 3 MEUR in funding, which we aim to use to finance our EUDOR-Y study as well as to develop EDOR® Interconnect and further develop both our hardware and our software.

Emotra has now been notified that our application will not be granted this time. We will be submitting a new, revised application as soon as possible.

A large number of leading international youth clinics, as many as 26 centres located in a large number of countries, have registered their interest in participating in EUDOR-Y. This is a clear sign of how important the psychiatric profession feels it is to evaluate EDOR® for testing of depressed young people. From the Company's viewpoint, this means that we need to start EUDOR-Y as soon as we have secured financing.

The market introduction of EDOR® will commence directly after conclusion of the analysis of our adult study EUDOR-A, which encompasses patients 18 years and older. Our plan is to complete this by the end of March, 2017. Naturally, our market launch is based on the study results meeting all of the Company's and the clinics' expectations.

Claes Holmberg, CEO, telephone: +46 708 25 45 47, E-mail: claes@emotra.se

Emotra AB (publ) is a medical technology company that carries out research, development, clinical studies and marketing in the area of suicide prevention. The Company's method, EDOR®, is a proprietary, objective and quantitative diagnostic, psychophysiological test for detecting hyporeactivity in patients suffering from depression. During the test, the patient listens to a series of audio signals. The patient's response, in the form of very small changes in dermal electric conductivity, is measured and analysed. This extremely sensitive and specific test of suicidal risk has been developed as the result of research.

Emotra AB (publ), Göteborgsvägen 74, SE-433 63 Sävedalen, Sweden Tel: +46 708 25 45 47, www.emotra.se